Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer

Review proposal consultation

Stakeholder matrix (PDF 219 KB)

Review proposal paper (PDF 496 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: Equality impact assessment - guidance development (PDF 160 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: final appraisal determination information

Lung cancer (non small cell, EGFR mutation positive) - afatinib: final appraisal determination document (PDF 366 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: evaluation report information

Lung cancer (non small cell, EGFR mutation positive) - afatinib: evaluation report (PDF 9.96 MB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: final scope (PDF 104 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: final matrix (PDF 111 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: response to consultee and commentator comments on the draft scope and provisional matrix (PDF 197 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: Equality Impact Assessment - scoping (PDF 121 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: provisional matrix - (pre referral) (PDF 100 KB)

Lung cancer (non small cell, EGFR mutation positive) - afatinib: draft scope - (pre referral) (PDF 109 KB)